^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

cucurbitacin I (JSI-124)

i
Other names: JSI 124, JSI-124, JSI124
Company:
H. Lee Moffitt Cancer Center and Research Institute, University of South Florida
Drug class:
JAK2 inhibitor, STAT3 inhibitor
3ms
Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization. (PubMed, Biochem Biophys Res Commun)
In terms of regulation on tumor microenvironment, cucurbitacin I was demonstrated the ability to inhibit HCC cell-induced M2 polarization of macrophages. This comprehensive study unveils the multifaceted anti-cancer mechanisms of cucurbitacin I, providing robust support for its potential application in the treatment of HCC, offering new avenues for the future development of HCC treatment strategies.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • E2F1 (E2F transcription factor 1) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
|
cucurbitacin I (JSI-124)
6ms
Plasmodium yoelii Infection Enhances the Expansion of Myeloid-Derived Suppressor Cells via JAK/STAT3 Pathway. (PubMed, J Immunol)
By inhibiting STAT3 phosphorylation with the JAK inhibitor JSI-124, effects of serum on MDSCs are almost eliminated. In vivo depletion of MDSCs with anti-Gr-1 or 5-fluorouracil significantly reduces the parasitemia and promotes Th1 immune response in P. yoelii-infected C57BL/6 mice by upregulating IFN-γ expression. In summary, this study indicates that P. yoelii infection facilitates the accumulation and function of MDSCs by upregulating the expression of Bcl2 and Arg1 via JAK/STAT3 signaling pathway in vivo and in vitro. Manipulating the JAK/STAT3 signaling pathway or depleting MDSCs could be promising therapeutic interventions to treat malaria.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • ARG1 (Arginase 1)
|
5-fluorouracil • cucurbitacin I (JSI-124)
9ms
Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer. (PubMed, Int J Oncol)
Moreover, the proportion of immunosuppressive cells including myeloid‑derived suppressor cells, T regulatory cells and M2‑polarized macrophages, decreased. These data suggested that CUIIa is a promising combination partner with DOX for liver cancer treatment, probably via triggering ICD and remolding the immune microenvironment.
Journal • IO biomarker
|
HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
|
doxorubicin hydrochloride • cucurbitacin I (JSI-124)
12ms
JSI-124 Induces Cell Cycle Arrest and Regulates the Apoptosis in Glioblastoma Cells. (PubMed, Biomedicines)
Collectively, our findings emphasize that JSI-124 holds potential as a therapeutic agent for GBM by impeding cell cycle progression, inhibiting cell proliferation, and promoting apoptosis. As demonstrated by our in vitro experiments, these effects are mediated through modulation of key molecular targets.
Journal
|
CASP3 (Caspase 3) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
|
cucurbitacin I (JSI-124)
12ms
Cucurbitacin I Reverses Tumor-Associated Macrophage Polarization to Affect Cancer Cell Metastasis. (PubMed, Int J Mol Sci)
These findings highlight the potential of cucurbitacin I as a therapeutic agent that targets M2-like macrophages to inhibit cancer cell metastasis. Our study provides novel insights into the intricate interplay among macrophage polarization, cucurbitacin I, and heme oxygenase-1, thereby opening new avenues for cancer treatment.
Journal
|
HMOX1 (Heme Oxygenase 1)
|
cucurbitacin I (JSI-124)
almost1year
Potential of cucurbitacin as an anticancer drug. (PubMed, Biomed Pharmacother)
Recent studies have identified cucurbitacins as promising molecules for therapeutic innovation with broad versatility in immune response. Thus, cucurbitacin is a promising class of anticancer agents that can be used alone or in combination with chemotherapy and radiotherapy for the treatment of many types of cancer.Therefore, based on the research reports in the past five years at home and abroad, we further summarize and review the structural characteristics, chemical and biological activities, and studies of cucurbitacins based on the previous studies to provide a reference for further development and utilization of cucurbitacins.
Review • Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
cucurbitacin I (JSI-124)
1year
JSI-124 inhibits cell proliferation and tumor growth by inducing autophagy and apoptosis in murine malignant mesothelioma. (PubMed, Mol Carcinog)
Autophagy inhibitors, Chloroquine (CQ) and Bafilomycin A1 (Baf-A1), inhibited autophagy and sensitized RN5 and AB12 cells to JSI-124-induced apoptosis. Our data indicate that JSI-124 is a promising therapeutic agent for MPM treatment.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2)
|
STAT3 expression • STAT3 overexpression
|
cucurbitacin I (JSI-124)
1year
Investigating EGFR-VEGF-mediated apoptotic effect of cucurbitacin D and I combination with sorafenib via Ras/Raf/MEK/ERK and PI3K/Akt signaling pathways. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
In this study, the anticarcinogenic effects of sorafenib-cucurbitacin D and sorafenib-cucurbitacin I combination on HepG2 cell line were investigated. The combined cucurbitacin-sorafenib applications inhibited the expression of proteins and genes involved in EGFR and PI3K/AKT/mTOR, Raf/MEK/ERK signaling pathways. Due to showing the synergetic effect of cucurbitacins with sorafenib and their targeting of similar signaling pathways reveal that their combination may increase the efficacy of sorafenib by suppressing angiogenic, metastatic and proliferative activity in HCC.
Journal
|
EGFR (Epidermal growth factor receptor) • BCL2L1 (BCL2-like 1) • MMP2 (Matrix metallopeptidase 2) • CASP9 (Caspase 9)
|
sorafenib • cucurbitacin I (JSI-124)
1year
A Novel Transgenic Mouse Model of Down Syndrome Acute Lymphoblastic Leukemia Identifies Targetable Vulnerabilities (ASH 2023)
We screened top candidate drugs in DS-ALL and non-DS ALL patient samples in vitro, and tested FK866 and cucurbitacin I in vivo in mice xenografted with a DS-ALL patient sample. We have generated the first de novo mouse model and cell lines recapitulating DS-ALL, which we have employed in drug screens to identify novel therapeutic approaches. These studies suggest promising candidates for further study in DS-ALL and other high-risk ALL subtypes to reduce toxicity and improve outcomes.
Preclinical
|
KRAS (KRAS proto-oncogene GTPase) • PAX5 (Paired Box 5) • NAMPT (Nicotinamide Phosphoribosyltransferase)
|
KRAS G12D • KRAS G12
|
daporinad (APO866) • cucurbitacin I (JSI-124)
1year
Inhibitory effect and molecular mechanism of sinomenine on human hepatocellular carcinoma HepG2 and SK-HEP-1 cells (PubMed, Zhongguo Zhong Yao Za Zhi)
Molecular docking was used to evaluate the strength of affinity of sinomenine to the target cysteinyl aspartate specific proteinase-3(caspase-3) and STAT3, and combined with CCK-8 assay to detect the changes in cell viability after combination with STAT3 inhibitor JSI-124 in combination with CCK-8 assay...Therefore, sinomenine can inhibit the proliferation and invasion of human hepatocellular carcinoma cells and induce apoptosis, and the mechanism may be attributed to the activation of caspase-3 signaling and inhibition of the Akt/mTOR/STAT3 pathway. This study can provide a new reference for the in-depth research and clinical application of sinomenine and is of great significance to further promote the scientific development and utilization of sinomenine.
Journal • PARP Biomarker
|
CASP3 (Caspase 3)
|
cucurbitacin I (JSI-124)
1year
Deacetylated Sialic Acid Sensitizes Lung and Colon Cancers to Novel Cucurbitacin-Inspired Estrone Epidermal Growth Factor Receptor (EGFR) Inhibitor Analogs. (PubMed, Molecules)
This observation correlated with significantly decreased levels of key downstream proteins (phosphorylated ERK and mTOR) of the EGFR pathway in knockout cells compared with controls when treated with CIEAs. Collectively, our findings indicate that Sia deacetylation renders lung and colon cancer cells susceptible to EGFR therapeutics and provide insights for future therapeutic interventions.
Journal
|
cucurbitacin I (JSI-124)
1year
Three candidate anticancer drugs were repositioned by integrative analysis of the transcriptomes of species with different regenerative abilities after injury. (PubMed, Comput Biol Chem)
Based on these gene signatures, we investigated 3 small compounds, namely cucurbitacin I, BMS-754807, and PHA-793887 as potential candidates for the treatment of cancer. Future studies on the mechanisms associated with the revealed gene signatures and anticancer effects of these three small compunds would allow scientists to develop therapeutic approaches to combat cancer. This research contributes to the evaluation of mechanisms and gene signatures that either limit or cause cancer, and to the development of new cancer therapies by establishing a link between regeneration and carcinogenesis.
Journal
|
BMS-754807 • cucurbitacin I (JSI-124) • PHA 793887
1year
Progranulin promoted the proliferation, metastasis, and suppressed apoptosis via JAK2-STAT3/4 signaling pathway in papillary thyroid carcinoma. (PubMed, Cancer Cell Int)
These findings revealed that PGRN promote the progression of PTC through the JAK2-STAT3/4 pathway, and PGRN could be served as a potential therapeutic target for PTC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • VIM (Vimentin) • CDH2 (Cadherin 2)
|
BCL2 expression • CCND1 expression • CDH1 expression • BAX expression • PGR expression • VIM expression
|
cucurbitacin I (JSI-124)
over1year
Cucurbitacin IIb Extracted from Hemsleya penxianensis Induces Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells by Regulating Cell Cycle Checkpoints and Mitochondrial Apoptotic Pathway. (PubMed, Plant Foods Hum Nutr)
Consistently, results of flow cytometry and AO/EB staining demonstrated that the growth-suppressive effect of CuIIb was mediated by cell cycle arrest in G2/M phase and robust induction of cell apoptosis, which was further confirmed by immunoblotting and mitochondrial membrane potential (ΔΨm) analysis. Collectively, the results presented herein indicated that CuIIb exhibited anticancer activity on bladder cancer which may be a potential candidate for improving bladder cancer outcomes.
Journal
|
cucurbitacin I (JSI-124)
2years
Cucurbitacin I exhibits anticancer efficacy through induction of apoptosis and modulation of JAK/STAT3, MAPK/ERK, and AKT/mTOR signaling pathways in HepG2 cell line. (PubMed, J Food Biochem)
DNA breaks are formed as a result of this effect. CuI, by reducing cell proliferation and promoting apoptosis, was found to have potential as a chemotherapeutic agent of hepatocellular carcinoma.
Preclinical • Journal
|
JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PI3K (Phosphoinositide 3-kinases)
|
cucurbitacin I (JSI-124)
2years
Standardized phytopreparations and cucurbitacin IIb from Ibervillea sonorae (S. Watson) greene induce apoptosis in cervical cancer cells by Nrf2 inhibition. (PubMed, J Ethnopharmacol)
Apoptotic activity of Etanison and Acetison was demonstrated in HeLa, due to the presence of caspase-9 and caspase-3 in western blot assays. Likewise, both the phytopreparations and CIIb showed inhibition of Nrf2, associating apoptotic activity with the inhibition of the GST transcription factor. In this sense, the phytopreparations of I. sonorae, as well as their derivatives, have the potential to obtain and develop anticancer products.
Journal
|
CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
cisplatin • cucurbitacin I (JSI-124)
over2years
Cucurbitacin B controls M2 macrophage polarization to suppresses metastasis via targeting JAK-2/STAT3 signalling pathway in colorectal cancer. (PubMed, J Ethnopharmacol)
Our results proved that cucurbitacin B might be a potential candidate agent for adjuvant therapy in the process of CRC growth and metastasis.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
CD8 expression • BAX expression • CD4 expression
|
cucurbitacin I (JSI-124)
almost3years
Hypoxia inducible factor-3α promotes osteosarcoma progression by activating KDM3A-mediated demethylation of SOX9. (PubMed, Chem Biol Interact)
The Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway inhibitor cucurbitacin I suppressed the promotive effects of HIF-3α overexpression on cell proliferation, invasion and TAK2/STAT3 pathway. Finally, OS cell line MG-63 transfected with HIF-3α short hairpin RNA (HIF-3α shRNA) were subcutaneously injected into nude mice, and the results found that HIF-3α knockdown significantly inhibited the xenograft tumor growth of OS in vivo. In conclusion, this study reveals that HIF-3α promotes OS progression in vitro and in vivo by activating KDM3A-mediated SOX9 promoter demethylation, which may provide a potential therapeutic mechanism for OS.
Journal
|
EPAS1 (Endothelial PAS domain protein 1) • SOX9 (SRY-Box Transcription Factor 9) • YBX1 (Y-Box Binding Protein 1)
|
SOX9 overexpression
|
cucurbitacin I (JSI-124)
3years
[VIRTUAL] STAT3 Inhibitor JSI-124 Induces Autophagic Cell Death in RN5 Murine Mesothelioma Cells (IMIG 2021)
RN5 cells were pretreated with 3-methyladenine (2.5 mM) or chloroquine (50 µM) for 1h, and then coincubation with JSI-124 for another 24 h. Levels of protein expression were analyzed by western blot using antibodies against caspase 3, PARP, MAP1LC3B-II, p-mTOR/p-p70S6K and p-JAK2/p-STAT3. STAT3 inhibitor JSI-124 induces protective autophagy in RN5 murine mesothelioma cells through mTOR/p70S6K signaling pathway, suggesting that JSI-124 may be a potential therapeutic strategy for MPM.
Preclinical • PARP Biomarker
|
PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3) • MAP1LC3B (Microtubule Associated Protein 1 Light Chain 3 Beta)
|
cucurbitacin I (JSI-124) • chloroquine phosphate
over3years
Co-culturing polarized M2 Thp-1-derived macrophages enhance stemness of lung adenocarcinoma A549 cells. (PubMed, Ann Transl Med)
The Hedgehog inhibitor (Vismodegib), Notch inhibitor Gamma Secretase Inhibitor (GSI), and Signal Transducer and Activator of Transcription 3 (STAT3) inhibitor Cucurbitacin I (JSI-124) were added separately into the co-culture system of A549 cancer cell with THP-1-derived macrophages. These results suggested that co-culturing A549 cells with THP-1-derived macrophages could induce the stemness of A549 cells via multiple pro-tumorigenic pathways. Thus, inhibition of the interaction between macrophages and lung cancer stem cells may be a viable target for lung cancer treatment in the future.
Journal
|
IL6 (Interleukin 6) • TGFB1 (Transforming Growth Factor Beta 1)
|
IL6 expression
|
Erivedge (vismodegib) • cucurbitacin I (JSI-124)
over3years
Cucurbitacin I (JSI-124)-dependent inhibition of STAT3 permanently suppresses the pro-carcinogenic effects of active breast cancer-associated fibroblasts. (PubMed, Mol Carcinog)
Together, these findings indicate that JSI-124-dependent inhibition of STAT3 could be of great therapeutic value for the treatment of breast cancer through targeting cancer cells as well as their growth supportive stromal fibroblasts and blood vessels. This could pave the path to developing a precise CAF-targeted anticancer therapy.
Journal
|
IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
cucurbitacin I (JSI-124)
4years
Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells. (PubMed, Biochem Biophys Rep)
We show that both cucurbitacins decrease viability and cause apoptosis in these cell lines, although HuT-78 was more affected than SeAx (IC of 17.38 versus 22.01 μM for cucurbitacin E and 13.36 versus 24.47 μM for cucurbitacin I)...Furthermore, while JAK2 inhibition leads to decreased viability in SeAx cells (IC of 9.98 and 29.15 μM for AZD1480 and ruxolitinib respectively), both JAK1 and JAK3 do not...Nevertheless, a role of STAT5 and JAK2 cannot be excluded and should be explored further. This knowledge could contribute to the development of effective therapies for CTCL and other malignancies involving dysfunction of the JAK/STAT pathway.
Journal
|
JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • JAK3 (Janus Kinase 3)
|
Jakafi (ruxolitinib) • AZD1480 • cucurbitacin I (JSI-124)
over4years
Cucurbitacin I induces apoptosis in ovarian cancer cells through oxidative stress and the p190B‑Rac1 signaling axis. (PubMed, Mol Med Rep)
Apoptosis was involved in the process of cucurbitacin I‑induced cell death, with an increase observed in cleaved‑caspase 3 and BAX, and a decrease in Bcl‑2...In brief, these results suggested that cucurbitacin I induced cell death through oxidative stress and the p190B‑Rac1 signaling axis in SKVO3 cells. The results may provide novel evidence for the treatment of ovarian cancer.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • CASP3 (Caspase 3)
|
cucurbitacin I (JSI-124)